Contact:
Karen S. Carolonza/Director, Strategic Communications and Public Relations, BD Medical Systems – 201-847-7033 (office), 908-313-8398 (cell)
Jack Segal/Edelman – 773-301-7983 (cell, June 8 and 9 at APIC meeting), 312-297-7425 (office)

San Antonio, TX (announced June 9, 2003, at Association for Professionals in Infection Control and Epidemiology (APIC) Annual Meeting) – BD, a leader in safety-engineered medical devices, today introduced its BD Vacutainer™ Push Button Blood Collection Set, a new technology designed to improve the safety of blood collection. The Push Button Blood Collection Set helps improve safety through its unique design: The needle automatically retracts into the device when the healthcare worker pushes the activation button with his or her index finger.

"Blood collection is one of the common causes of the more than 500,000¹ needlestick injuries that occur among U.S. healthcare workers annually," said William A. Kozy, president, BD Clinical Laboratory Solutions. "The launch of this next generation device represents a major technological advancement in a market that has seen moderate improvement in the last decade. It raises the bar on innovation in this important area."

Healthcare workers say they would activate safety mechanisms
The U.S. Occupational Safety and Health Administration (OSHA) requires that employers incorporate engineering and work practice controls to eliminate or minimize employee exposure to bloodborne pathogens (bloodborne pathogens include HIV, HBV and HCV). However, these efforts are effective only if healthcare workers comply: Research² indicates that healthcare workers activate safety features on current blood collection devices 83 percent of the time. "BD has designed the Push Button Blood Collection Set to make activating its safety mechanism easy," said Kozy.

To this end, BD was encouraged by feedback from the 86 healthcare workers at four hospitals in three states, and 13 additional phlebotomists, who participated in pre-launch clinical trials of the device: The vast majority "strongly agreed" that they would always activate the Push Button Blood Collection Set's safety mechanism.

The Push Button Blood Collection Set is intuitive, easy to use
Trial participants also strongly agreed that the device is intuitive and easy to use. On average, participants reported they felt comfortable using the Push Button Blood Collection Set after only three venipunctures. A recent multi-hospital evaluation³ of phlebotomy devices found that almost half of clinicians did not feel comfortable until five or more uses of a new device. In addition, healthcare workers can operate the Push Button Blood Collection Set using only one hand, allowing them to attend to the venipuncture site with the other hand. Based on its design, as well as feedback from healthcare workers, BD anticipates that training requirements will be minimal.

The Push Button Blood Collection Set, which received FDA clearance for both blood collection and short-term infusion, incorporates BD needle technology, which is among the sharpest in the industry.

BD's long standing commitment to safety
The introduction of the BD Vacutainer™ Push Button Blood Collection Set further extends BD's already broad array of safety-engineered products. BD's range of safety products includes more than 200 catalog items for injection, infusion therapy, sample collection, surgery and sharps disposal. BD pioneered the development of safety-engineered medical devices and has been at the forefront of this field for well over a decade.

In an effort to enhance healthcare worker safety, BD has announced its intent to phase out U.S. sales of many conventional sharps devices across a range of product categories, including IV catheters, winged needle sets and lancets. BD will provide safety-engineered devices in all of these categories.

For more information, contact the BD Inside Sales Group at 1-800-817-1702 or visit www.bd.com/vacutainer.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2002, BD reported total revenues of $4.03 billion.

BD's news releases can be found on its website at www.bd.com. To arrange interviews about the Push Button Blood Collection Set, contact Karen S. Carolonza, director, Strategic Communications and Public Relations, BD Medical Systems, at 201-847-7033 or 908-313-8398.

¹ "Healthcare Worker Blood Exposure Risks: Correcting Some Outdated Statistics: Advances in Exposure Prevention," (Vol. 6, No. 3, 2003, pp. 28 – 31) Jane Perry, MA, and Janine Jagger, MPH, PhD
² "Evaluation of a Safety Resheathable Winged Steel Needle for Prevention of Percutaneous Injuries Associated with Intravascular-Access Procedures Among Healthcare Workers," Infection Control and Hospital Epidemiology (Vol. 24, No. 2, Feb. 2003): Meryl H. Mendelson, MD; Bao Ying Lin-Chen, MPH; Robin Solomon, RN, MS; Eileen Bailey, RN, MPH; Gene Kogan, MS; James Goldbold, PhD
³ "Sharp Safety Device Field Evaluation Results:" Gina Pugliese, RN, MS. Premier Safety Institute (www.premierinc.com/safety)

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; BD's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in health care or other governmental regulation, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.